All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Joon Ho MoonDuring the 2021 Korean Society of Hematology International Conference & 62nd Annual Meeting (ICKSH 2021), the ALL Hub spoke to Joon Ho Moon, Kyungpook National University, Daegu, KR. We asked, How is relapsed/refractory ALL currently managed in Korea? Moon kindly gave his interview in Korean, with the title '한국의 재발성 및 불응성 급성림프구성백혈병의 치료'.
How is relapsed/refractory ALL currently managed in Korea? (KR)
In this video, Moon discusses the available therapy options used in Korea for patients with ALL, including immunotherapy, chemotherapy, and allogeneic transplantation.
Your opinion matters
On average, how many patients with B-cell acute lymphoblastic leukemia do you see in a year?